Navigation Links
arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
Date:7/8/2010

ROTTERDAM, The Netherlands, July 8, 2010 /PRNewswire/ --

- Novel Platform Set to Transform Human Therapeutic Antibody Discovery & Development

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

The broad granted patent covers arGEN-X's SIMPLE Antibody(TM) technology, which yields gold standard human therapeutic antibodies with an unmatched functional diversity. It also covers arGEN-X's antibody products as well as methods of generating them. arGEN-X is prosecuting additional patent applications globally, which when granted will provide the company with an unrivalled IP position in the human antibody space.

arGEN-X' SIMPLE Antibody(TM) platform utilizes the active immunization of outbred Camelids with a target antigen to rapidly deliver highly diverse antibodies whose variable regions are nearly identical to those of human antibodies. arGEN-X then uses these to produce variable antibody regions with 96-99% human sequence homology via minimal germlining (humanization). This is easily achieved without any loss in affinity and potency in just a matter of weeks. These variable domains are then combined with human constant domains to generate full size, fully human therapeutic antibodies.

A further key attraction of the SIMPLE Antibody(TM) platform is its unique ability to generate incredibly diverse panels of ultra-potent antibodies to a broad range of targets, including intractable and conserved targets. These antibo
'/>"/>

SOURCE arGEN-X
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
2. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
3. BSP Granted CE Mark for its HyperQ AD-100 Product Enabling Improved Diagnostic Performance of Stress ECG
4. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
5. MultiCell Technologies Is Granted European Patent for the Treatment of Cancer
6. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
7. Acuo Technologies Announces Patent Granted for Asset Communication Format Within a Computer Network
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. SPO Medical Granted Innovative Baby Monitoring Patent
10. First iPierian Patent for Induced Pluripotent Stem Cell Technology Granted by United Kingdom Intellectual Property Office
11. FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... -- Diseases largely eradicated in the United ... was declared eliminated in 2000, yet the CDC reports ... highest incidence in 20 years. In July, ... a problem of "epidemic proportions." ... these preventable diseases—in part because some parents (more than ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... Ala., Dec. 14 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... data evaluating forodesine HCl, the Company,s lead anti-cancer,compound, ... and lymphomas., Madeline Duvic, M.D., Deputy Chair, ... presented interim data from the Phase,I/II clinical study ...
... the Treatment of PKU, NOVATO, Calif., Dec. ... announced today that the U.S.,Food and Drug Administration ... Tablets, the first specific drug,therapy approved for the ... will commence tomorrow, and BioMarin will begin,promotion of ...
Cached Medicine Technology:Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 2Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 3Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma 4BioMarin Announces FDA Approval for Kuvan 2BioMarin Announces FDA Approval for Kuvan 3BioMarin Announces FDA Approval for Kuvan 4BioMarin Announces FDA Approval for Kuvan 5BioMarin Announces FDA Approval for Kuvan 6BioMarin Announces FDA Approval for Kuvan 7BioMarin Announces FDA Approval for Kuvan 8
(Date:8/29/2014)... a systematic review of clinical trials based on ... researchers have concluded that more trials are needed ... for postsurgical pain on a regular basis., Dr. ... pain research in the Department of Anesthesiology, and ... to determine whether the use of antidepressants for ...
(Date:8/29/2014)... Colo. (Sept. 2, 2014) A team of scientists ... reported the breakthrough discovery of a process to expand ... These findings could have implications that extend beyond cancer, ... autoimmune diseases., In an article published Aug. ... Charles C. Gates Center for Regenerative Medicine and Stem ...
(Date:8/29/2014)... Mass. (August 29, 2014, 2 PM US Eastern ... is to inject antibodies, commonly produced in animals, ... challenges ranging from safety to difficulties in developing, ... , New research led by Charles Shoemaker, ... and Global Health at the Cummings School of ...
(Date:8/29/2014)... EDMONTON, AB A new study from the research group ... AB) and the Lawson Health Research Institute (London, ON) has ... of cancer. The study, published in Cell Reports , ... spread of cancer entirely. , Roughly 2 in 5 ... four of them will die of the disease. In 2014, ...
(Date:8/29/2014)... Francisco, CA (PRWEB) August 30, 2014 ... 10 best web conference providers in the online service ... the list were global leaders Webex, GotoMeeting and Infinite. ... the industry users have to determine which provider is ... Essentially, web conference businesses search for compelling consumer goods ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:CU scientists' discovery could lead to new cancer treatment 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Preventing cancer from forming 'tentacles' stops dangerous spread 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... WASHINGTON, Sept. 2 Speaker Nancy Pelosi and Senate Majority Leader Harry Reid ... Session of Congress on Wednesday, September 9, 2009. , , ... , September 2, 2009 , , President Barack ... Dear Mr. President: , , Our nation is closer than ever ...
... ATLANTA, Sept. 2 /PRNewswire-FirstCall/ -- Gentiva Health Services, Inc. ... health services, announced today that it has completed its acquisition of ... the Rush Health System, located in central Mississippi and west central ... , "We extend a warm welcome to all ...
... , , WASHINGTON, Sept. ... President, Campaign for Tobacco-Free Kids: , , (Logo: ... have taken decisive action to protect the state,s kids and taxpayers from ... by $1 to $3.00 per pack, making it the second highest state ...
... Study found more than half of advanced basal cell carcinomas ... -- An experimental cancer drug that switches off the so-called ... patients with advanced basal cell carcinoma, a type of skin ... from medulloblastoma, the most common form of brain cancer in ...
... , OAKLAND, Calif., Sept. 2 Wigix ( ... database on the web. Wigix has surpassed Overstock.com and ... (Source: Internet Retailers Top 500 Guide 2009 Edition) , , ... thousand SKUs during its public beta launch in June 2007. This milestone marks ...
... , , , ... the House Democrat healthcare bill (H.R. 3200) that violate President Obama,s promise ... $250,000 per year. The White House has told reporters that Obama ... week, which begs the question: , , ...
Cached Medicine News:Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 2Health News:Gentiva(R) Health Services Completes Acquisition of Home Health Agency 3Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 2Health News:Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers; $1 Increase Gives State Second Highest Cigarette Tax in the Nation 3Health News:New Compound Shrinks Skin Cancers 2Health News:New Compound Shrinks Skin Cancers 3Health News:New Compound Shrinks Skin Cancers 4Health News:Wigix Announces 1 Million in Open Sell Orders 2Health News:Obama's 'Specific' Healthcare Speech: Will He Disavow Pledge-Breaking Tax Hikes in House Dem Health Bill? 2
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Inquire...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
The Fujinon's R410 laparoscope is the first to bring a 410,000 pixel CCD to the end of the scope. Superior imaging and color replication, along with a unique lens washing capability make the R410 the...
Medicine Products: